acodazole profile

Acodazole is a potent microtubule-stabilizing agent that has shown promising preclinical activity against a range of cancers. Its mechanism of action involves binding to tubulin, a protein that forms microtubules, and preventing their depolymerization. This stabilization of microtubules leads to disruption of cell division and ultimately cell death. Acodazole has been investigated for its potential as a treatment for various cancers, including breast cancer, lung cancer, and leukemia. Studies have demonstrated its ability to inhibit tumor growth and induce apoptosis in cancer cells. Acodazole’s unique mechanism of action and its ability to overcome resistance to other microtubule-targeting drugs make it a promising candidate for further clinical development. Research efforts are ongoing to explore its efficacy and safety in human patients.'

ID Source	ID
PubMed CID	41446
CHEMBL ID	188427
SCHEMBL ID	156653
MeSH ID	M0144439

Synonym
NCI60_002602
NCIMECH_000457
acodazole
bdbm50154462
n-methyl-n-[4-(7-methyl-1h-imidazo[4,5-f]quinolin-9-ylamino)-phenyl]-acetamide
nci-305884
CHEMBL188427 ,
79152-85-5
8m28a9o41g ,
n-methyl-4'-((7-methyl-1h-imidazo(4,5-f)quinolin-9-yl)amino)acetanilide
acodazol [spanish]
acodazole [inn]
acodazolum
acodazol
n-methyl-4'-((7-methyl-1h-imidazo(4,5-f)chinolin-9-yl)amino)acetanilid
acetamide, n-methyl-n-(4-((7-methyl-1h-imidazo(4,5-f)quinolin-9-yl)amino)phenyl)-
unii-8m28a9o41g
acodazolum [latin]
CCG-35586
acodazole [who-dd]
SCHEMBL156653
DTXSID20229559
1h-imidazo(4,5-f)quinoline, acetamide deriv.
XJXLRNPVSQADMZ-UHFFFAOYSA-N
n-methyl-n-(4-[(7-methyl-1h-imidazo[4,5-f]quinolin-9-yl)amino]phenyl)acetamide #
Q27270734
n-methyl-n-[4-[(7-methyl-6h-imidazo[4,5-f]quinolin-9-yl)amino]phenyl]acetamide
acetamide,n-methyl-n-[4-[(7-methyl-1h-imidazo[4,5-f]quinolin-9-yl)amino]phenyl]-
AKOS040745470

Excerpt	Reference	Relevance
"Acodazole (NSC 305884) is a synthetic imidazoquinoline which has antimicrobial as well as antineoplastic properties. "	( Phase I clinical trial and pharmacokinetic evaluation of acodazole (NSC 305884), an imidazoquinoline derivative with electrophysiological effects on the heart. Alberti, D; Grem, J; Koeller, J; Remick, S; Simon, K; Tormey, DC; Trump, DL; Tutsch, KD; Willson, JK, 1987)	1.96

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	18.1000	0.0000	2.0151	10.0000	AID240619
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID658164	Stabilization of human G-quadruplex F21T assessed as change in melting temperature at 5 uM by FRET assay	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Identification of novel telomeric G-quadruplex-targeting chemical scaffolds through screening of three NCI libraries.
AID658163	Stabilization of DNA duplex hairpin structure assessed as change in melting temperature at 1 uM by FRET assay	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Identification of novel telomeric G-quadruplex-targeting chemical scaffolds through screening of three NCI libraries.
AID658162	Stabilization of human G-quadruplex F21T assessed as change in melting temperature at 1 uM by FRET assay	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Identification of novel telomeric G-quadruplex-targeting chemical scaffolds through screening of three NCI libraries.
AID240619	Inhibitory concentration against cytochrome P450 2D6	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (60.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	1 (20.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.	2.02	1	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	2.02	1	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
hycanthone Hycanthone: Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE.. hycanthone : A thioxanthen-9-one compound having a hydroxymethyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. It was formerly used (particularly as the monomethanesulfonic acid salt) as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel.	2.02	1	thioxanthenes	mutagen; schistosomicide drug
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	2.02	1	dihydroxyanthraquinone	analgesic; antineoplastic agent
nortriptyline Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.	2.02	1	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
tolonium chloride Tolonium Chloride: A phenothiazine that has been used as a hemostatic, a biological stain, and a dye for wool and silk. Tolonium chloride has also been used as a diagnostic aid for oral and gastric neoplasms and in the identification of the parathyroid gland in thyroid surgery.. tolonium chloride : An organic chloride salt having 3-amino-7-(dimethylamino)-2-methylphenothiazin-5-ium (tolonium) as the counterion. It is a blue nuclear counterstain that can be used to demonstrate Nissl substance and is also useful for staining mast cell granules, both in metachromatic and orthochromatic techniques.	2.07	1
yohimbine Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.	2.02	1	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
acridines Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.	1.96	1	acridines; mancude organic heterotricyclic parent; polycyclic heteroarene	genotoxin
dequalinium chloride dequalinium chloride : An organic chloride salt that is the dichloride salt of dequalinium.	2.07	1	organic chloride salt	antifungal agent; antineoplastic agent; antiseptic drug; mitochondrial NADH:ubiquinone reductase inhibitor
Berberine chloride (TN) [no description available]	2.07	1	organic molecular entity
amonafide xanafide: salt formulation of amonafide; DNA-intercalating agent and topoisomerase II inhibitor	2.02	1	isoquinolines
lm 985 LM 985: structure given in first source; RN given refers to parent cpd	2.02	1
nsc 38280 [no description available]	2.07	1
bay h 2049 batracylin: structure given in first source	2.02	1
cinchonine [no description available]	2.02	1	(8xi)-cinchonan-9-ol; cinchona alkaloid	metabolite
sr 2555 [no description available]	2.02	1
dihydrolenperone dihydrolenperone: structure given in first source	2.02	1
hepsulfam hepsulfam: structure given in first source	2.02	1
taspine taspine: RN given refers to parent cpd; structure	2.07	1
nsc 314622 NSC 314622: structure in first source	2.07	1
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	2.02	1	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
bruceantin [no description available]	2.02	1	triterpenoid
braco-19 BRACO-19: structure in first source	2.07	1	acridines; N-alkylpyrrolidine
nk 5 NK 5: antioxidant containing divalent cations of iron, manganese, & cobalt	2.07	1	organic iodide salt; quinolines	fluorochrome

Condition	Relationship Strength	Studies
Breast Cancer [description not available]	1.97	1
Cancer of Gastrointestinal Tract [description not available]	1.97	1
Cancer of Lung [description not available]	2.37	2
Sarcoma, Epithelioid [description not available]	1.97	1
Genito-urinary Cancer [description not available]	1.97	1
Breast Neoplasms Tumors or cancer of the human BREAST.	1.97	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.37	2
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	1.97	1
Urogenital Neoplasms Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.	1.97	1
Cancer of Colon [description not available]	1.97	1
Electrocardiogram QT Prolonged [description not available]	1.97	1
Benign Neoplasms [description not available]	1.97	1
Cancer of Rectum [description not available]	1.97	1
Colonic Neoplasms Tumors or cancer of the COLON.	1.97	1
Long QT Syndrome A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.	1.97	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1.97	1
Rectal Neoplasms Tumors or cancer of the RECTUM.	1.97	1

acodazole

Cross-References

Synonyms (29)

Research Excerpts

Overview

Protein Targets (1)

Inhibition Measurements

Biological Processes (16)

Molecular Functions (8)

Ceullar Components (5)

Bioassays (4)

Research

Studies (5)

Study Types